Top Page
BioNTech SE
(NASDAQ:BNTX)
BioNTech SE (BNTX) vs. SPDR S&P 500 ETF (SPY)
BioNTech SE Business Overview & Revenue Model
BioNTech SE Earnings Call Summary
BioNTech SE Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.88B | 2.75B | 3.82B | 17.31B | 18.98B | 482.32M |
| Gross Profit | 2.30B | 2.21B | 3.22B | 12.78B | 15.12B | -222.04M |
| EBITDA | -227.60M | -367.10M | 1.09B | 12.86B | 15.73B | -97.89M |
| Net Income | -347.44M | -665.30M | 930.30M | 9.43B | 10.29B | 15.20M |
Balance Sheet | ||||||
| Total Assets | 21.64B | 22.53B | 23.01B | 23.28B | 15.83B | 2.32B |
| Cash, Cash Equivalents and Short-Term Investments | 14.04B | 16.78B | 16.55B | 14.06B | 2.07B | 1.35B |
| Total Debt | 269.60M | 254.20M | 219.10M | 212.20M | 301.50M | 240.19M |
| Total Liabilities | 3.13B | 3.12B | 2.76B | 3.22B | 3.94B | 946.77M |
| Stockholders Equity | 18.51B | 19.41B | 20.25B | 20.06B | 11.89B | 1.37B |
Cash Flow | ||||||
| Free Cash Flow | -2.54B | -244.60M | 4.67B | 13.21B | 735.70M | -98.92M |
| Operating Cash Flow | -1.72B | 207.70M | 5.37B | 13.58B | 889.70M | -13.47M |
| Investing Cash Flow | 1.69B | -2.08B | -6.95B | -35.30M | -566.10M | -144.85M |
| Financing Cash Flow | -42.30M | -45.90M | -778.60M | -1.42B | 94.20M | 894.73M |
BioNTech SE Technical Analysis
BioNTech SE Risk Analysis
BioNTech SE Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | $50.69B | 38.15 | 24.75% | ― | 89.58% | ― | |
74 Outperform | $18.37B | 14.79 | 26.08% | ― | 23.25% | 64.46% | |
61 Neutral | ― | ― | ― | ― | 730.42% | 31.63% | |
60 Neutral | $60.94B | -188.08 | -257.82% | ― | 5.01% | -330.09% | |
57 Neutral | $25.70B | ― | -1.81% | ― | 7.51% | 30.53% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $10.74B | ― | -27.50% | ― | -38.95% | 51.07% |
BioNTech SE Corporate Events
On October 22, 2025, BioNTech SE announced the commencement of a public exchange offer for all outstanding shares of CureVac N.V., as part of a strategic acquisition to enhance its capabilities in mRNA-based cancer immunotherapy. This acquisition is expected to strengthen BioNTech’s research, development, manufacturing, and commercialization efforts, marking a significant milestone in its oncology strategy. The transaction, valued at approximately $1.25 billion, aims to create long-term value for shareholders and advance the development of innovative cancer treatments.
On October 1, 2025, BioNTech SE, in collaboration with InstaDeep Ltd., hosted its second AI Day as part of its Innovation Series. The event highlighted BioNTech’s AI strategy and its application in the company’s pipeline and internal processes. This initiative underscores BioNTech’s commitment to leveraging AI to advance its position in the biotechnology industry, potentially impacting its operational efficiency and stakeholder engagement.
On September 8, 2025, BioNTech SE and Bristol Myers Squibb presented interim data from a Phase 2 trial evaluating pumitamig, a bispecific antibody, in patients with extensive-stage small cell lung cancer. The data showed promising antitumor activity, with a 76.3% confirmed objective response rate and a 100% disease control rate, suggesting potential for pumitamig to become a new standard of care in this aggressive cancer type. The trial’s results are being used to inform a global Phase 3 trial, and pumitamig has received Orphan Drug designation from the FDA.
On June 2, 2025, BioNTech SE entered into a Global Co-Development and Co-Commercialization Agreement with Bristol-Myers Squibb Company to develop, manufacture, and commercialize the bispecific antibody BNT327 for various solid tumor types. The agreement, which was amended on August 15, 2025, includes a $1.5 billion upfront payment to BioNTech and up to $7.6 billion in additional milestone payments. The collaboration will see both companies sharing profits and losses equally, with a focus on maximizing the success and efficiency of BNT327’s development and commercialization. This strategic partnership is expected to enhance BioNTech’s position in the oncology market and provide significant financial benefits.
On September 5, 2025, BioNTech SE and Duality Biologics announced that their Phase 3 trial in China for trastuzumab pamirtecan (BNT323/DB-1303) met its primary endpoint of progression-free survival in patients with HER2-positive metastatic breast cancer. This milestone marks the first positive Phase 3 data from their strategic collaboration, highlighting the potential of trastuzumab pamirtecan as a new treatment option. The success of this trial strengthens BioNTech’s position in oncology and supports further development of the drug in other regions, including the U.S. and EU.
On August 27, 2025, BioNTech SE and Pfizer Inc. announced that the U.S. Food and Drug Administration approved their LP.8.1-adapted monovalent COVID-19 vaccine, COMIRNATY® LP.8.1, for adults aged 65 and older, and individuals aged 5 through 64 with underlying conditions at high risk for severe COVID-19 outcomes. This approval is based on extensive clinical and real-world data demonstrating the vaccine’s safety and efficacy. The vaccine targets the SARS-CoV-2 sublineage LP.8.1, aligning with FDA guidance to address circulating strains. Shipping of the vaccine will commence immediately to ensure availability in pharmacies, hospitals, and clinics across the U.S., reinforcing BioNTech’s and Pfizer’s positions in the vaccine market and their commitment to addressing public health needs.
On August 7, 2025, BioNTech SE, along with its partners Pfizer and CureVac, reached a settlement to resolve ongoing patent litigation related to COVID-19 vaccines in the United States. The agreement includes dismissing existing claims and granting BioNTech a non-exclusive license for mRNA-based vaccines in the U.S. and worldwide, contingent on the acquisition of CureVac. The settlement involves significant financial transactions, including payments to GSK and CureVac, and sets a framework for resolving international disputes, impacting BioNTech’s operational and strategic positioning in the vaccine market.
On August 4, 2025, BioNTech SE released its financial results for the three and six months ending June 30, 2025. The company reported increased revenues compared to the previous year, reflecting its ongoing efforts in research and development. This financial update highlights BioNTech’s strong market position and its commitment to advancing its product pipeline, which is crucial for stakeholders and investors.
On August 4, 2025, BioNTech SE announced its financial results for the second quarter of 2025, reporting revenues of €260.8 million and a net loss of €386.6 million. The company highlighted significant strategic moves, including a collaboration with Bristol Myers Squibb to advance its BNT327 antibody candidate and the acquisition of CureVac to enhance its mRNA capabilities. These developments are expected to strengthen BioNTech’s financial position and expand its oncology strategy. The company also received approval for a new variant-adapted COVID-19 vaccine from the European Commission, with preparations for its launch underway.
On July 25, 2025, BioNTech SE and Pfizer Inc. announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use recommended marketing authorization for their LP.8.1-adapted COVID-19 vaccine, COMIRNATY® LP.8.1. This vaccine is designed for individuals aged 6 months and older to prevent COVID-19 caused by SARS-CoV-2. The recommendation is based on data showing improved immune responses against current and emerging variants compared to previous formulations. The European Commission’s decision is pending, and the companies have already started manufacturing to ensure readiness for the upcoming vaccination season. This development is expected to strengthen BioNTech’s position in the vaccine market and address the evolving needs of COVID-19 immunization.